Endocrine

, Volume 42, Issue 2, pp 375–381

Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency

  • Linman Li
  • Wei Ren
  • Jinchao Li
  • Jingjing Liu
  • Lingli Wang
  • Xiaoya Zheng
  • Dezhen Liu
  • Sufang Li
  • Rhonda Souvenir
  • Jiping Tang
Original Article

Abstract

Adult Growth Hormone Deficiency (AGHD) is correlated to many adverse effects on metabolism and increased cardiovascular risk. Pregnancy-associated plasma protein-A (PAPP-A) is a protease that promotes IGF-I availability in vascular tissues in recent study, and PAPP-A levels have been proposed as an early predictor of cardiac events. The aim of our study was to compare PAPP-A levels in AGHD patients with that of healthy adult subjects to determine if there is a relationship between serum PAPP-A and glucose and lipid metabolism. Twenty AGHD patients and 20 healthy, age-matched and weight-matched persons were chosen for the study. Their weight, height, blood pressure, body mass index (BMI), body fat percentage, waist and hip circumference, and waist–hips ratio were assessed. An oral glucose tolerance test was performed and venous blood was collected from the each patient’s cubital vein for biochemical analysis. Serum PAPP-A level in AGHD patients was significantly higher than that of the control group [(7.62 ± 1.62 vs. 6.54 ± 1.31) p < 0.05], and PAPP-A was positively correlated to age, BMI, waist circumference and so on. After adjusting for the waist circumference, waist–hip ratio, 2 h postprandial blood glucose, triglycerides, the serum PAPP-A in AGHD patients was positively correlated to the BMI (r = 0.728, p < 0.05) and fasting insulin (r = 0.433, p < 0.05). In a multiple step-wise regression analysis, BMI, 2 h postprandial glucose, fasting insulin, HOMA-IR were independently associated with serum PAPP-A in AGHD patients. The increase in serum PAPP-A levels is associated with abnormal glucose metabolism and increased risk of atherosclerosis in AGHD patients.

Keyword

Adult growth hormone deficiency Serum pregnancy-associated plasma protein-A Insulin tolerance test 

References

  1. 1.
    H.L. Fideleff, A. Chervin, A. Giaccio, P. Sobrado, R. Barmat et al., Adult growth hormone deficiency. Metabolic alterations and evaluation of different risk groups. Medicina (B Aires) 64, 13–19 (2004)Google Scholar
  2. 2.
    A. Sanmartí, A. Lucas, F. Hawkins, S.M. Webb, A. Ulied, Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status. Collaborative ODA (observational GH deficiency in adults) group. Eur. J. Endocrinol. 141, 481–489 (1999)PubMedCrossRefGoogle Scholar
  3. 3.
    B. Bülow, L. Hagmar, C.H. Nordström, Z. Mikoczy, E.M. Erfurth, Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. 46, 75–81 (1997)CrossRefGoogle Scholar
  4. 4.
    J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton et al., Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357, 425–431 (2001)PubMedCrossRefGoogle Scholar
  5. 5.
    J. Svensson, B.-A. Bengtsson, T. Rosén, A. Odén, G. Johannsson et al., Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J. Clin. Endocrinol. Metab. 89, 3306–3312 (2004)PubMedCrossRefGoogle Scholar
  6. 6.
    M. Gola, S. Bonadonna, M. Doga, G. Mazziotti, A. Giustina, Cardiovascular risk in aging and obesity: is there a role for GH. J. Endocrinol. Invest. 28, 759–767 (2005)PubMedGoogle Scholar
  7. 7.
    B. Bulow, L. Hangmar, J. Eskilsson, E.M. Erfurth, Hypopituitary females have a high incidence of cardiovascular morbidity and increased prevalence of cardiovascular risk factors. J. Clin. Endocrinol. Metab. 85, 574–584 (2000)PubMedCrossRefGoogle Scholar
  8. 8.
    A. Colao, C. Di Somma, S. Spiezia, S. Savastano, F. Rota et al., Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J. Clin. Endocrinol. Metab. 93, 3416–3424 (2008)PubMedCrossRefGoogle Scholar
  9. 9.
    P.H. Su, S.F. Yang, J.S. Yu, S.J. Chen, J.Y. Chen, Study of the leptin levels and its gene polymorphisms in patients with idiopathic short stature and growth hormone deficiency. Endocrine (2012 in press)Google Scholar
  10. 10.
    A. Colao, C. Di Somma, M.C. Savanelli, M. De Leo, G. Lombardi, Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm. IGF Res. 16(Suppl A), S41–S48 (2006)PubMedCrossRefGoogle Scholar
  11. 11.
    T. Mueller, B. Dieplinger, W. Poelz, M. Haltmayer, Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study. Clin. Chem. 52, 1096–1103 (2006)PubMedCrossRefGoogle Scholar
  12. 12.
    J.L. Beaudeux, L. Burc, F. Imbert-Bismut, P. Giral, M. Bernard et al., Serum/plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in a symptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 23, e7–e10 (2003)PubMedCrossRefGoogle Scholar
  13. 13.
    C. Heeschen, S. Dimmeler, C.W. Hamm, S. Fichtlscherer, M.L. Simoons et al., Pregnancy associated plasma protein-A levels in patients with acute coronary syndromes:comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 45, 229–237 (2005)PubMedCrossRefGoogle Scholar
  14. 14.
    M. Doga, S. Bonadonna, M. Gola, G. Mazziotti, A. Giustina, Growth hormone deficiency in the adult. Pituitary 9, 305–311 (2006)PubMedCrossRefGoogle Scholar
  15. 15.
    J.B. Lawrence, C. Oxvig, M.T. Overgaard, L. Sottrup-Jensen, G.J. Gleich et al., The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc. Natl. Acad. Sci. USA 96, 3149–3153 (1999)PubMedCrossRefGoogle Scholar
  16. 16.
    M.T. Overgaard, C. Oxvig, M. Christiansen, J.B. Lawrence, C.A. Conover et al., Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonproductive tissues. Biol. Reprod. 61, 1083–1089 (1999)PubMedCrossRefGoogle Scholar
  17. 17.
    G.A. Bayes, C.A. Conover, M.T. Overgaard, K.R. Bailey, M. Christiansen et al., Pregnancy-associated plasm a protein-A as a marker of acute coronary syndromes. N. Engl. J. Med. 345, 1022–1029 (2001)CrossRefGoogle Scholar
  18. 18.
    H.B. Boldt, M.T. Overgaard, L.S. Laursen, K. Weyer, L. Sottrup-Jensen et al., Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin. Biochem J 358, 267–359 (2001)CrossRefGoogle Scholar
  19. 19.
    C. Joaquin, E. Aguilera, M.L. Granada, M.C. Pastor, I. Salinas et al., Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur. J. Endocrinol. 158, 483–490 (2008)PubMedCrossRefGoogle Scholar
  20. 20.
    D. González-Duarte, A. Madrazo-Atutxa, A. Soto-Moreno, A. Leal-Cerro, Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency. Pituitary (2012 in press)Google Scholar
  21. 21.
    C.A. Conover, L.K. Bale, S.C. Harrington, Z.T. Resch, M.T. Overgaard, C. Oxvig, Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol. Am. J. Physiol. Cell Physiol. 290, C183–C188 (2006)PubMedCrossRefGoogle Scholar
  22. 22.
    A.L. Carrel, D.B. Allen, Effects of growth hormone on body composition and bone metabolism. Endocrine 12, 163–172 (2000)PubMedCrossRefGoogle Scholar
  23. 23.
    R. Sode-Carlsen, S. Farholt, K.F. Rabben, J. Bollerslev, T. Schreiner et al., Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine 41, 191–199 (2012)PubMedCrossRefGoogle Scholar
  24. 24.
    J.R. Sowers, Obesity as a cardiovascular risk factor. Am. J. Med. 115, 37–41 (2003)CrossRefGoogle Scholar
  25. 25.
    J.O. Johansson, J. Fowelin, K. Landin, I. Lager, B.A. Bengtsson, Growth hormone-deficient adults are insulin-resistant. Metabolism 44, 1126–1129 (1995)PubMedCrossRefGoogle Scholar
  26. 26.
    R. Arumugam, D. Fleenor, M. Freemark, Effects of lactogen resistance and GH deficiency on mouse metabolism: pancreatic hormones, adipocytokines, and expression of adiponectin and insulin receptors. Endocrine 32, 182–191 (2007)PubMedCrossRefGoogle Scholar
  27. 27.
    J. Ukropec, A. Penesová, M. Skopková, M. Pura, M. Vlcek et al., Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements. J. Clin. Endocrinol. Metab. 93, 2255–2262 (2008)PubMedCrossRefGoogle Scholar
  28. 28.
    N. Vahl, I. Klausen, J.S. Christiansen, J.O. Jørgensen, Growth hormone status is an independent determinant of serum levels of cholesterol and triglycerides in healthy subjects. Clin. Endocrinol. 51, 309–316 (1999)CrossRefGoogle Scholar
  29. 29.
    R. Abs, U. Feldt-Rasmussen, A.F. Mattsson, J.P. Monson, B.A. Bengtsson et al., Determinants of cardiovascular risk in 2,589 hypopituitary growth hormone-deficient adults. Eur. J. Endocrinol. 155, 79–90 (2006)PubMedCrossRefGoogle Scholar
  30. 30.
    Y. Momiyama, R. Ohmori, Z.A. Fayad, T. Kihara, N. Tanaka et al., Association between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. J. Atheroscler. Thromb. 17, 460–467 (2010)PubMedCrossRefGoogle Scholar
  31. 31.
    A. Juul, T. Scheike, M. Davidsen, J. Gyllenborg, T. Jørgensen, Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106, 939–944 (2002)PubMedCrossRefGoogle Scholar
  32. 32.
    K.K. Miller, T. Wexler, P. Fazeli, L. Gunnell, G.J. Graham et al., Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J. Clin. Endocrinol. Metab. 95, 567–577 (2010)PubMedCrossRefGoogle Scholar
  33. 33.
    C. Beauregard, A.L. Utz, A.E. Schaub, L. Nachtigall, B.M. Biller et al., Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 93, 2063–2071 (2008)PubMedCrossRefGoogle Scholar
  34. 34.
    K.A. Al-Shoumer, K. Ali, V. Anyaoku, R. Niththyananthan, D.G. Johnston, Overnight metabolic fuel deficiency in patients treated conventionally for hypopituitarism. Clin. Endocrinol. (Oxf) 45, 171–178 (1996)CrossRefGoogle Scholar
  35. 35.
    Y. Kato, H.Y. Hu, M. Sohmiya, Short-term treatment with different doses of human growth hormone in adult patients with growth hormone deficiency. Endocr. J. 43, 177–183 (1996)PubMedCrossRefGoogle Scholar
  36. 36.
    E. Kousta, A. Chrisoulidou, N.J. Lawrence, V. Anyaoku, K.A. Al-Shoumer et al., The effects of growth hormone replacement therapy on over night metabolic fuels in hypopituitary patients. Clin. Endocrinol. (Oxf) 52, 17–24 (2000)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Linman Li
    • 1
  • Wei Ren
    • 1
  • Jinchao Li
    • 1
  • Jingjing Liu
    • 1
  • Lingli Wang
    • 1
  • Xiaoya Zheng
    • 1
  • Dezhen Liu
    • 1
  • Sufang Li
    • 1
  • Rhonda Souvenir
    • 2
  • Jiping Tang
    • 2
  1. 1.The First Affiliated HospitalChongqing Medical UniversityChongqingChina
  2. 2.Department of Basic ScienceLoma Linda UniversityLoma LindaUSA

Personalised recommendations